Kexing Pharmaceuticals: Approved for new indications and specifications of human erythropoietin products_Oriental Fortune Network

Summary

[Kexing Pharmaceuticals: Application for New Indications and Specifications of Human Erythropoietin Products Approved]Kexing Pharmaceuticals announced on February 14 that the company received the “Approval Notice for Supplementary Drug Application” approved and issued by the State Food and Drug Administration. On the basis of the original approved indications and specifications, the drug Human Erythropoietin Injection has a new indication of “anemia caused by chemotherapy for non-myeloid malignant tumors” and a new specification of 36000IU/1ml/tube.

　　Sinovac PharmaceuticalsFebruary 14announcementAccording to the company, the company has received the “Approval Notice for Supplementary Drug Application” approved and issued by the State Food and Drug Administration, and its drug human erythropoietin injection, on the basis of the original approved indications and specifications, adds “the treatment of non-myeloid malignant tumors caused by chemotherapy. “Anemia” indications and new specifications of 36000IU/1ml/piece.

It is understood that in the treatment of “anemia caused by chemotherapy of non-myeloid malignant tumors”, the large-scale human erythropoietin product of 36,000IU/1ml/piece can significantly reduce the frequency of medication, and under the premise of equal efficacy, it can greatly improve the patient’s medication compliance.

The announcement stated that the supplementary application approval for the new indications and new specifications of human erythropoietin injection will help expand the market share of the drug in the field of oncology, further enhance the market competitiveness of the product, and play a positive role in the company’s business development. .

(Article source: ChinasecuritiesReport · China Securities Network)

Article source: China Securities Journal China Securities Network

Responsible editor: 33

Original title: Kexing Pharma: The application for new indications and specifications of human erythropoietin products was approved